Impact of Comprehensive Metabolic Optimization on Myocardial steatosis and Cardiac Remodeling in newly diagnosed type 2 diabetes: a longitudinal study
Abstract
Abstract Background Cardiac remodeling is common in individuals with type 2 diabetes (T2D) and may be influenced by both glycemic and metabolic factors. On the other hand, myocardial steatosis, a hallmark of diabetic cardiomyopathy, has been inconsistently linked to glycemic control. This study aimed to evaluate the impact of comprehensive metabolic optimization—targeting improvements in both glycemic control and adiposity— on myocardial triglyceride content (MTGC) and cardiac remodeling in newly diagnosed. Methods Twenty adults with newly diagnosed T2D underwent a 12-month standardized metabolic optimization protocol including insulin, metformin, and empagliflozin therapy, alongside nutritional and lifestyle counseling. Cardiac magnetic resonance imaging (CMR) and proton magnetic resonance spectroscopy ( 1 H-MRS) were performed at baseline and after 12 months to assess cardiac structure, function, and myocardial triglyceride content (MTGC). Analyses assessed longitudinal changes and explored associations among clinical, biochemical, and imaging parameters. Results Participants (mean age 54.8 ± 9 years, 72.3% male) achieved significant reduction in HbA1c, body mass index (BMI) and waist circumference (WC) after 12 months of glycemic optimization. No significant changes in MTGC were found at follow up (0.52% [0.25–1.44] vs 1.05% [0.43–3.06]; p = 0.23). In contrast, CMR parameters showed favorable remodeling with improved left ventricular ejection fraction Left Ventricle(LV)…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.